Henderson Michael's most recent trade in Apogee Therapeutics Inc. was a trade of 75,046 Common Stock done . Disclosure was reported to the exchange on July 8, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Jul 2026 | 75,046 | 920,941 | - | 0 | Common Stock | |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 133.63 per share. | 08 Jul 2026 | 20,000 | 995,987 | - | 133.6 | 2,672,600 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 132.54 per share. | 22 Jun 2026 | 80,000 | 1,015,987 | - | 132.5 | 10,603,200 | Common Stock |
| Spyre Therapeutics Inc | Michael Henderson | Director | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 22 Jun 2026 | 20,000 | 68,606 (0%) | 0% | 100 | 2,000,000 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 82.78 per share. | 10 Jun 2026 | 7,654 | 1,101,563 | - | 82.8 | 633,598 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 82.21 per share. | 10 Jun 2026 | 6,770 | 1,109,217 | - | 82.2 | 556,562 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 86.27 per share. | 10 Jun 2026 | 2,305 | 1,096,601 | - | 86.3 | 198,852 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 85.19 per share. | 10 Jun 2026 | 1,577 | 1,098,906 | - | 85.2 | 134,345 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 84.18 per share. | 10 Jun 2026 | 1,080 | 1,100,483 | - | 84.2 | 90,914 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 86.89 per share. | 10 Jun 2026 | 614 | 1,095,987 | - | 86.9 | 53,350 | Common Stock |
| Spyre Therapeutics Inc | Michael Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2026 | 8,026 | 8,026 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 82.05 per share. | 13 May 2026 | 18,659 | 1,117,328 | - | 82.1 | 1,530,971 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 82.58 per share. | 13 May 2026 | 1,341 | 1,115,987 | - | 82.6 | 110,740 | Common Stock |
| Spyre Therapeutics Inc | Michael Henderson | Director | Sale of securities on an exchange or to another person at price $ 73.72 per share. | 08 May 2026 | 33,513 | 132,689 (0%) | 0% | 73.7 | 2,470,578 | Common Stock |
| Spyre Therapeutics Inc | Michael Henderson | Director | Sale of securities on an exchange or to another person at price $ 74.76 per share. | 08 May 2026 | 24,814 | 107,875 (0%) | 0% | 74.8 | 1,855,095 | Common Stock |
| Spyre Therapeutics Inc | Michael Henderson | Director | Sale of securities on an exchange or to another person at price $ 75.35 per share. | 08 May 2026 | 19,269 | 88,606 (0%) | 0% | 75.3 | 1,451,919 | Common Stock |
| Spyre Therapeutics Inc | Michael Henderson | Director | Sale of securities on an exchange or to another person at price $ 72.57 per share. | 08 May 2026 | 2,404 | 166,202 (0%) | 0% | 72.6 | 174,458 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 3,000 | 387,012 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.86 per share. | 16 Apr 2026 | 3,000 | 1,135,987 | - | 22.9 | 68,580 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 82.48 per share. | 08 Apr 2026 | 17,800 | 1,135,187 | - | 82.5 | 1,468,144 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 83.26 per share. | 08 Apr 2026 | 2,000 | 1,133,187 | - | 83.3 | 166,520 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 85.00 per share. | 08 Apr 2026 | 200 | 1,132,987 | - | 85 | 17,000 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.29 per share. | 11 Mar 2026 | 8,363 | 1,164,624 | - | 74.3 | 621,287 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.83 per share. | 11 Mar 2026 | 8,219 | 1,156,405 | - | 74.8 | 615,028 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 75.86 per share. | 11 Mar 2026 | 3,418 | 1,152,987 | - | 75.9 | 259,289 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 62.96 per share. | 11 Feb 2026 | 11,494 | 1,181,493 | - | 63.0 | 723,662 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 63.73 per share. | 11 Feb 2026 | 7,551 | 1,173,942 | - | 63.7 | 481,225 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 64.99 per share. | 11 Feb 2026 | 955 | 1,172,987 | - | 65.0 | 62,065 | Common Stock |
| Spyre Therapeutics Inc | Michael Henderson | Director | Other type of transaction at price $ 0.00 per share. | 21 Jan 2026 | 63,227 | 168,606 (0%) | 0% | 0 | Common Stock | |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 79.82 per share. | 14 Jan 2026 | 8,476 | 1,203,071 | - | 79.8 | 676,554 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 83.16 per share. | 14 Jan 2026 | 5,386 | 1,193,457 | - | 83.2 | 447,900 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 81.00 per share. | 14 Jan 2026 | 2,374 | 1,200,697 | - | 81 | 192,294 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 82.41 per share. | 14 Jan 2026 | 1,854 | 1,198,843 | - | 82.4 | 152,788 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 78.64 per share. | 14 Jan 2026 | 1,440 | 1,211,547 | - | 78.6 | 113,242 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 83.79 per share. | 14 Jan 2026 | 470 | 1,192,987 | - | 83.8 | 39,381 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 253,016 | 253,016 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 75.79 per share. | 10 Dec 2025 | 10,005 | 1,213,547 | - | 75.8 | 758,279 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.88 per share. | 10 Dec 2025 | 9,435 | 1,223,552 | - | 74.9 | 706,493 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 76.58 per share. | 10 Dec 2025 | 560 | 1,212,987 | - | 76.6 | 42,885 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 75.01 per share. | 04 Dec 2025 | 40,000 | 1,232,987 | - | 75.0 | 3,000,400 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 63.14 per share. | 13 Nov 2025 | 14,774 | 1,274,873 | - | 63.1 | 932,830 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 61.93 per share. | 13 Nov 2025 | 3,340 | 1,289,647 | - | 61.9 | 206,846 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 63.89 per share. | 13 Nov 2025 | 1,786 | 1,273,087 | - | 63.9 | 114,108 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 64.52 per share. | 13 Nov 2025 | 100 | 1,272,987 | - | 64.5 | 6,452 | Common Stock |
| Spyre Therapeutics Inc | Michael Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 29.98 per share. | 05 Mar 2025 | 7,326 | 1,295,661 | - | 30.0 | 219,633 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 30.62 per share. | 05 Mar 2025 | 2,674 | 1,292,987 | - | 30.6 | 81,878 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 40.58 per share. | 05 Feb 2025 | 15,000 | 1,302,987 | - | 40.6 | 608,700 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.86 per share. | 31 Jan 2025 | 8,500 | 1,317,987 | - | 22.9 | 194,310 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 8,500 | 390,012 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc | Michael Henderson | Director | Other type of transaction at price $ 0.00 per share. | 10 Jan 2025 | 105,379 | 105,379 (0%) | 0% | 0 | Common Stock | |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2024 | 357,036 | 357,036 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 46.50 per share. | 04 Dec 2024 | 13,328 | 1,326,159 | - | 46.5 | 619,752 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 47.19 per share. | 04 Dec 2024 | 1,672 | 1,324,487 | - | 47.2 | 78,902 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 59.17 per share. | 06 Nov 2024 | 14,000 | 1,340,487 | - | 59.2 | 828,380 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 59.94 per share. | 06 Nov 2024 | 1,000 | 1,339,487 | - | 59.9 | 59,940 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 56.07 per share. | 02 Oct 2024 | 30,288 | 1,364,199 | - | 56.1 | 1,698,248 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 56.74 per share. | 02 Oct 2024 | 9,712 | 1,354,487 | - | 56.7 | 551,059 | Common Stock |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Sale of securities on an exchange or to another person at price $ 27.21 per share. | 06 Sep 2024 | 38,000 | 76,828 (0%) | 0% | 27.2 | 1,033,900 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 47.28 per share. | 04 Sep 2024 | 25,641 | 1,408,846 | - | 47.3 | 1,212,306 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 48.23 per share. | 04 Sep 2024 | 14,359 | 1,394,487 | - | 48.2 | 692,535 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 40.40 per share. | 07 Aug 2024 | 32,233 | 1,442,254 | - | 40.4 | 1,302,213 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 41.52 per share. | 07 Aug 2024 | 7,667 | 1,434,587 | - | 41.5 | 318,334 | Common Stock |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.17 per share. | 07 Aug 2024 | 100 | 1,434,487 | - | 42.2 | 4,217 | Common Stock |
| Arya Sciences Acquisition Corp | Michael Henderson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Jul 2024 | 30,000 | 0 | - | - | Class B ordinary shares | |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 37.26 per share. | 05 Jul 2024 | 15,000 | 1,474,487 | - | 37.3 | 558,900 | Common Stock |
| Spyre Therapeutics Inc | Michael Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2024 | 11,323 | 11,323 | - | - | Stock Option (Right to Buy) | |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Sale of securities on an exchange or to another person at price $ 27.60 per share. | 25 Mar 2024 | 37,500 | 114,828 (0%) | 0% | 27.6 | 1,034,854 | Common Stock |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2024 | 13,889 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Sale of securities on an exchange or to another person at price $ 27.59 per share. | 25 Mar 2024 | 13,889 | 114,828 (0%) | 0% | 27.6 | 383,198 | Common Stock |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.47 per share. | 25 Mar 2024 | 13,889 | 128,717 (0%) | 0% | 10.5 | 145,418 | Common Stock |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 40,650 | 167,394 (0%) | 0% | 0 | Common Stock | |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.60 per share. | 01 Mar 2024 | 15,066 | 152,328 (0%) | 0% | 24.6 | 370,624 | Common Stock |
| Marathon Oil Corporation | Michael Henderson A. | Executive VP, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 53,570 | 147,824 (0%) | 0% | 0 | Common Stock | |
| Marathon Oil Corporation | A. Henderson Michael | Executive VP, Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.85 per share. | 31 Jan 2024 | 21,080 | 126,744 (0%) | 0% | 22.9 | 481,678 | Common Stock |
| Apogee Therapeutics Inc | Henderson Michael | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 398,512 | 398,512 | - | - | Stock Option (Right to Buy) | |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Sale of securities on an exchange or to another person at price $ 27.30 per share. | 28 Sep 2023 | 37,000 | 94,254 (0%) | 0% | 27.3 | 1,010,174 | Common Stock |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Sale of securities on an exchange or to another person at price $ 26.91 per share. | 01 Sep 2023 | 20,000 | 131,254 (0%) | 0% | 26.9 | 538,234 | Common Stock |
| Radius Recycling Inc | Michael R. Henderson | SVP, President, Operations | Sale of securities on an exchange or to another person at price $ 27.44 per share. | 04 May 2023 | 1,691 | 132,769 (0%) | 0% | 27.4 | 46,401 | Class A Common Stock |
| Radius Recycling Inc | Michael R. Henderson | SVP, President, Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.89 per share. | 01 May 2023 | 1,656 | 134,460 (0%) | 0% | 28.9 | 47,842 | Class A Common Stock |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 31,795 | 162,149 (0%) | 0% | 0 | Common Stock | |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.79 per share. | 01 Mar 2023 | 10,895 | 151,254 (0%) | 0% | 25.8 | 280,982 | Common Stock |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.86 per share. | 17 Feb 2023 | 9,020 | 130,354 (0%) | 0% | 25.9 | 233,257 | Common Stock |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 47,755 | 153,005 (0%) | 0% | 0 | Common Stock | |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.86 per share. | 25 Jan 2023 | 13,631 | 139,374 (0%) | 0% | 27.9 | 379,760 | Common Stock |
| Radius Recycling Inc | Michael R. Henderson | SVP, President, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2022 | 12,421 | 136,116 (0%) | 0% | 0 | Class A Common Stock | |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Sale of securities on an exchange or to another person at price $ 32.56 per share. | 08 Nov 2022 | 80,000 | 105,250 (0%) | 0% | 32.6 | 2,604,448 | Common Stock |
| Radius Recycling Inc | Michael R. Henderson | SVP, President, Operations | Sale of securities on an exchange or to another person at price $ 26.36 per share. | 03 Nov 2022 | 16,823 | 123,695 (0%) | 0% | 26.4 | 443,454 | Class A Common Stock |
| Radius Recycling Inc | Michael R. Henderson | SVP, President, Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2022 | 27,062 | 155,449 (0%) | 0% | 0 | Class A Common Stock | |
| Radius Recycling Inc | Michael R. Henderson | SVP, President, Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.99 per share. | 31 Oct 2022 | 9,732 | 145,717 (0%) | 0% | 27.0 | 262,667 | Class A Common Stock |
| Radius Recycling Inc | Michael R. Henderson | SVP, President, Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.99 per share. | 31 Oct 2022 | 5,199 | 140,518 (0%) | 0% | 27.0 | 140,321 | Class A Common Stock |
| Radius Recycling Inc | Michael R. Henderson | SVP, President, Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.63 per share. | 02 May 2022 | 1,792 | 128,387 (0%) | 0% | 45.6 | 81,769 | Class A Common Stock |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Sale of securities on an exchange or to another person at price $ 24.73 per share. | 22 Mar 2022 | 40,000 | 185,250 (0%) | 0% | 24.7 | 989,144 | Common Stock |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.47 per share. | 22 Mar 2022 | 27,777 | 213,027 (0%) | 0% | 10.5 | 290,825 | Common Stock |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Mar 2022 | 27,777 | 13,889 | - | - | Employee Stock Option (Right to Buy) | |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Sale of securities on an exchange or to another person at price $ 24.73 per share. | 22 Mar 2022 | 27,777 | 185,250 (0%) | 0% | 24.7 | 686,872 | Common Stock |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Sale of securities on an exchange or to another person at price $ 24.73 per share. | 22 Mar 2022 | 23,529 | 185,250 (0%) | 0% | 24.7 | 581,863 | Common Stock |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Mar 2022 | 23,529 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.79 per share. | 22 Mar 2022 | 23,529 | 208,779 (0%) | 0% | 16.8 | 395,052 | Common Stock |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2022 | 27,174 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Marathon Oil Corporation | Michael A. Henderson | Executive VP, Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.52 per share. | 07 Mar 2022 | 27,174 | 252,424 (0%) | 0% | 14.5 | 394,566 | Common Stock |